Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Physiol ; 600(2): 233-259, 2022 01.
Article in English | MEDLINE | ID: mdl-34339523

ABSTRACT

NMDA receptors (NMDARs) are glutamate-gated ion channels that play key roles in synaptic transmission and plasticity. Both hyper- and hypo-activation of NMDARs are deleterious to neuronal function. In particular, NMDAR hypofunction is involved in a wide range of neurological and psychiatric conditions like schizophrenia, intellectual disability, age-dependent cognitive decline, or Alzheimer's disease. While early medicinal chemistry efforts were mostly focused on the development of NMDAR antagonists, the last 10 years have seen a boom in the development of NMDAR positive allosteric modulators (PAMs). Here we review the currently developed NMDAR PAMs, their pharmacological profiles and mechanisms of action, as well as their physiological effects in healthy animals and animal models of NMDAR hypofunction. In light of the complexity of physiological outcomes of NMDAR PAMs in vivo, we discuss the remaining challenges and questions that need to be addressed to better grasp and predict the therapeutic potential of NMDAR positive allosteric modulation.


Subject(s)
Alzheimer Disease , Receptors, N-Methyl-D-Aspartate , Allosteric Regulation , Animals , Glutamic Acid , Receptors, N-Methyl-D-Aspartate/metabolism , Synaptic Transmission
2.
Bioorg Med Chem ; 28(18): 115655, 2020 09 15.
Article in English | MEDLINE | ID: mdl-32828422

ABSTRACT

Structural modifications of the neuronal calcium channel blocker MONIRO-1, including constraining the phenoxyaniline portion of the molecule and replacing the guanidinium functionality with tertiary amines, led to compounds with significantly improved affinities for the endogenously expressed CaV2.2 channel in the SH-SY5Y neuroblastoma cell line. These analogues also showed promising activity towards the CaV3.2 channel, recombinantly expressed in HEK293T cells. Both of these ion channels have received attention as likely targets for the treatment of neuropathic pain. The dibenzoazepine and dihydrobenzodiazepine derivatives prepared in this study show an encouraging combination of neuronal calcium ion channel inhibitory potency, plasma stability and potential to cross the blood-brain-barrier.


Subject(s)
Anilides/chemical synthesis , Antineoplastic Agents/chemical synthesis , Benzodiazepines/chemistry , Calcium Channel Blockers/chemical synthesis , Calcium Channels/metabolism , Neuralgia/drug therapy , Recombinant Proteins/metabolism , Anilides/metabolism , Animals , Antineoplastic Agents/metabolism , Antineoplastic Agents/pharmacology , Blood-Brain Barrier/metabolism , Calcium/metabolism , Calcium Channel Blockers/metabolism , Calcium Channel Blockers/pharmacology , Calcium Channels/genetics , Cell Line, Tumor , Drug Screening Assays, Antitumor , Humans , Models, Molecular , Neurons/metabolism , Rats, Sprague-Dawley , Recombinant Proteins/genetics , Signal Transduction , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...